National Bank of Canada FI Has $15.72 Million Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

National Bank of Canada FI grew its position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 62.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 235,266 shares of the company's stock after acquiring an additional 90,739 shares during the quarter. National Bank of Canada FI owned about 0.06% of Moderna worth $15,723,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Sequoia Financial Advisors LLC increased its holdings in Moderna by 7.1% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 8,722 shares of the company's stock valued at $1,036,000 after purchasing an additional 575 shares in the last quarter. Wedmont Private Capital raised its holdings in shares of Moderna by 48.4% during the 2nd quarter. Wedmont Private Capital now owns 3,075 shares of the company's stock valued at $373,000 after buying an additional 1,003 shares during the period. Wealth Enhancement Advisory Services LLC boosted its holdings in Moderna by 8.3% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 11,894 shares of the company's stock worth $1,412,000 after acquiring an additional 914 shares during the period. Baader Bank Aktiengesellschaft grew its position in Moderna by 27.2% in the second quarter. Baader Bank Aktiengesellschaft now owns 4,134 shares of the company's stock valued at $471,000 after acquiring an additional 884 shares in the last quarter. Finally, Swedbank AB raised its stake in shares of Moderna by 9.6% during the second quarter. Swedbank AB now owns 34,099 shares of the company's stock valued at $4,049,000 after purchasing an additional 2,993 shares during the period. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on MRNA shares. Leerink Partners decreased their price target on shares of Moderna from $60.00 to $48.00 and set an "underperform" rating for the company in a research report on Tuesday, September 17th. TD Cowen lowered their target price on Moderna from $70.00 to $60.00 and set a "hold" rating for the company in a report on Friday, September 13th. UBS Group cut their price target on Moderna from $140.00 to $108.00 and set a "buy" rating on the stock in a report on Thursday, October 24th. Royal Bank of Canada restated a "sector perform" rating and set a $75.00 price objective on shares of Moderna in a research report on Thursday, September 19th. Finally, Hsbc Global Res raised Moderna from a "hold" rating to a "strong-buy" rating in a research report on Monday, November 18th. Four investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Moderna currently has a consensus rating of "Hold" and an average target price of $79.50.

Moderna Stock Up 3.3 %

NASDAQ MRNA traded up $1.35 on Wednesday, reaching $42.86. The stock had a trading volume of 5,615,165 shares, compared to its average volume of 4,976,789. Moderna, Inc. has a 1 year low of $35.80 and a 1 year high of $170.47. The business has a 50 day moving average price of $49.39 and a 200 day moving average price of $85.62. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $16.49 billion, a price-to-earnings ratio of -7.13 and a beta of 1.58.

Moderna (NASDAQ:MRNA - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, beating analysts' consensus estimates of ($1.89) by $1.92. The business had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. Moderna's revenue for the quarter was up 3.8% on a year-over-year basis. During the same quarter last year, the firm earned ($1.39) EPS. On average, analysts forecast that Moderna, Inc. will post -9.32 EPS for the current fiscal year.

Insider Buying and Selling at Moderna

In other news, CFO James M. Mock sold 715 shares of Moderna stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $60.12, for a total transaction of $42,985.80. Following the sale, the chief financial officer now owns 9,505 shares of the company's stock, valued at approximately $571,440.60. This trade represents a 7.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Shannon Thyme Klinger sold 1,418 shares of the firm's stock in a transaction on Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the transaction, the insider now directly owns 19,717 shares of the company's stock, valued at approximately $843,690.43. This trade represents a 6.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 3,379 shares of company stock worth $158,195 over the last ninety days. Company insiders own 15.70% of the company's stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.